Some friendly caution: I have spoken with several biotech execs (and I know two personally, in Philadelphia) and they are always upbeat and confident. They have hope, like we do. They are not arbiters of a drug's efficacy or partnership potential, they are advocates and agents of them. Ours are competent, and typical of small biotech. (I should note also that if a CRO is used, management is as in the dark about blinded results as shareholders, unless they get a planned contractual interim report. This is probably a surprise to most retail speculators. They are not advantaged.)
For the shareholders, far more important than being upbeat is being vigilant, objective, and patient. You don't need rah-rah and grandiose claims, you need results. We're getting a big one soon, looking forward to it.
Market Data 
Markets 
AI
